New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment Journal Article
| Authors: | Ladanyi, M.; Zauderer, M. G.; Krug, L. M.; Ito, T.; McMillan, R.; Bott, M.; Giancotti, F. |
| Article Title: | New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment |
| Abstract: | Malignant pleural mesothelioma (MPM) is a highly lethal cancer with limited therapeutic options. Recent work has focused on the frequent somatic inactivation of two tumor suppressor genes in MPM-NF2 (Neurofibromatosis type 2) and the recently identified BAP1 (BRCA associated protein 1). In addition, germline mutations in BAP1 have been identified that define a new familial cancer syndrome, which includes MPM,ocular melanoma, and other cancers. These recent advances may allow screening of high-risk individuals and the development of new therapies that target key pathways in MPM. ©2012 AACR. |
| Journal Title: | Clinical Cancer Research |
| Volume: | 18 |
| Issue: | 17 |
| ISSN: | 1078-0432 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2012-09-01 |
| Start Page: | 4485 |
| End Page: | 4490 |
| Language: | English |
| DOI: | 10.1158/1078-0432.ccr-11-2375 |
| PROVIDER: | scopus |
| PMCID: | PMC3432735 |
| PUBMED: | 22825583 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 1 October 2012" - "CODEN: CCREF" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work